Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib versus teriflunomide in relapsing multiple sclerosis
NL-OMON54887Phase 3Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of evobrutinib in multiple sclerosis (MS), sponsored by Merck KGaA. Started Oct 2020; status: active, not recruiting.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON54887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54887.